These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19396006)

  • 1. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
    Bland AE; Stone R; Heuser C; Shu J; Jazaeri A; Shutter J; Atkins K; Rice L
    Int J Gynecol Cancer; 2009 Feb; 19(2):261-5. PubMed ID: 19396006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
    Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
    Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
    Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
    Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
    Tong SY; Lee JM; Choi YJ; Lee JK; Kim JW; Cho CH; Kim SM; Park SY; Park CY; Kim KT
    Aust N Z J Obstet Gynaecol; 2012 Feb; 52(1):44-8. PubMed ID: 22188343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.
    Zhang L; Shimizu D; Killeen JL; Honda SA; Lu D; Stanoyevitch A; Lin F; Wang B; Monuki ES; Carbone M
    Hum Pathol; 2016 Jul; 53():159-67. PubMed ID: 26980026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
    Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
    Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival.
    George E; Lillemoe TJ; Twiggs LB; Perrone T
    Int J Gynecol Pathol; 1995 Jan; 14(1):39-44. PubMed ID: 7883424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor.
    Sinkre P; Albores-Saavedra J; Miller DS; Copeland LJ; Hameed A
    Int J Gynecol Pathol; 2000 Apr; 19(2):127-32. PubMed ID: 10782408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological features of malignant mixed mesodermal tumor: analysis of 50 cases].
    Ding XH; Ma ZY; Wang YF; Dou FX; Yuan J; Tian X; Liu AJ
    Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1008-1013. PubMed ID: 34496490
    [No Abstract]   [Full Text] [Related]  

  • 13. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma.
    Swisher EM; Gown AM; Skelly M; Ek M; Tamimi HK; Cain JM; Greer BE; Muntz HG; Goff BA
    Gynecol Oncol; 1996 Jan; 60(1):81-8. PubMed ID: 8557233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
    Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
    Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.
    Ambros RA; Sherman ME; Zahn CM; Bitterman P; Kurman RJ
    Hum Pathol; 1995 Nov; 26(11):1260-7. PubMed ID: 7590702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
    Zhu M; Jia N; Huang F; Liu X; Zhao Y; Tao X; Jiang W; Li Q; Feng W
    BMC Cancer; 2017 Oct; 17(1):696. PubMed ID: 29061125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors.
    Zelmanowicz A; Hildesheim A; Sherman ME; Sturgeon SR; Kurman RJ; Barrett RJ; Berman ML; Mortel R; Twiggs LB; Wilbanks GD; Brinton LA
    Gynecol Oncol; 1998 Jun; 69(3):253-7. PubMed ID: 9648597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct histological and clinical features associated with pure uterine serous carcinoma: A single institution experience.
    Zhi W; Zhan Y; He C; Jin Y
    Ann Diagn Pathol; 2023 Oct; 66():152173. PubMed ID: 37352704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
    Rice LW; Stone RL; Xu M; Galgano M; Stoler MH; Everett EN; Jazaeri AA
    Am J Obstet Gynecol; 2006 Apr; 194(4):1119-26; discussion 1126-8. PubMed ID: 16580307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.